NO20032614D0 - Farmasöytisk sammensetning med forbedret absorbabilitet - Google Patents

Farmasöytisk sammensetning med forbedret absorbabilitet

Info

Publication number
NO20032614D0
NO20032614D0 NO20032614A NO20032614A NO20032614D0 NO 20032614 D0 NO20032614 D0 NO 20032614D0 NO 20032614 A NO20032614 A NO 20032614A NO 20032614 A NO20032614 A NO 20032614A NO 20032614 D0 NO20032614 D0 NO 20032614D0
Authority
NO
Norway
Prior art keywords
pharmaceutical composition
improved absorbability
absorbability
improved
pharmaceutical
Prior art date
Application number
NO20032614A
Other languages
English (en)
Other versions
NO20032614L (no
Inventor
Eiji Nara
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of NO20032614D0 publication Critical patent/NO20032614D0/no
Publication of NO20032614L publication Critical patent/NO20032614L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20032614A 2000-12-11 2003-06-10 Farmasöytisk sammensetning som har forbedret absorberbarhet NO20032614L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000375608 2000-12-11
PCT/JP2001/010827 WO2002048142A1 (en) 2000-12-11 2001-12-11 Medicinal compositions having improved absorbability

Publications (2)

Publication Number Publication Date
NO20032614D0 true NO20032614D0 (no) 2003-06-10
NO20032614L NO20032614L (no) 2003-08-05

Family

ID=18844596

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032614A NO20032614L (no) 2000-12-11 2003-06-10 Farmasöytisk sammensetning som har forbedret absorberbarhet

Country Status (10)

Country Link
US (1) US20040053972A1 (no)
EP (1) EP1350793A1 (no)
KR (1) KR20040025881A (no)
CN (1) CN1487936A (no)
AU (1) AU2002221115A1 (no)
CA (1) CA2431322A1 (no)
HU (1) HUP0400683A2 (no)
NO (1) NO20032614L (no)
PL (1) PL362172A1 (no)
WO (1) WO2002048142A1 (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984653B2 (en) 2001-10-05 2006-01-10 Takeda Pharmaceutical Company Limited Heterocyclic compounds, oxazole derivatives, process for preparation of the same and use thereof
TWI324597B (en) * 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
WO2005028469A1 (en) * 2003-09-19 2005-03-31 Astrazeneca Ab Quinazoline derivatives
PT1671635E (pt) * 2003-10-08 2012-01-17 Meiji Seika Pharma Co Ltd Composição de antibiótico amorfo contendo cefditoreno pivoxil
US7259262B2 (en) 2003-10-24 2007-08-21 Hoffmann-La Roche Inc. Arylazole derivatives, their manufacture and use as pharmaceutical agents
JP4639745B2 (ja) * 2004-01-19 2011-02-23 青葉化成株式会社 難固結性のタンパク質変性抑制剤粉末およびその使用方法
JP4982084B2 (ja) * 2004-02-09 2012-07-25 株式会社サンギ 抗腫瘍剤
JP2008519047A (ja) * 2004-11-05 2008-06-05 セフアロン・インコーポレーテツド 癌処置
US8436190B2 (en) * 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
US8623405B2 (en) * 2005-01-28 2014-01-07 Takeda Pharmaceutical Company Limited Finely divided composition containing poorly water soluble substance
JP5097540B2 (ja) * 2005-04-06 2012-12-12 株式会社サンギ 腸管吸収用抗腫瘍剤
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
EP2303276B1 (en) 2008-05-13 2013-11-13 AstraZeneca AB Fumarate salt of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(n-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline
US7749300B2 (en) * 2008-06-05 2010-07-06 Xerox Corporation Photochemical synthesis of bimetallic core-shell nanoparticles
EP2326306A1 (en) 2008-09-25 2011-06-01 Cephalon, Inc. Liquid formulations of bendamustine
NZ594010A (en) * 2009-01-15 2013-08-30 Cephalon Inc Novel forms of bendamustine free base
BR122020010643B1 (pt) * 2011-10-14 2022-05-17 Array Biopharma Inc Dispersão sólida, composições farmacêuticas compreendendo a referida dispersão, usos das composições farmacêuticas e processo de preparação de uma dispersão sólida

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
AU4314196A (en) * 1994-12-21 1996-07-10 Yamanouchi Pharmaceutical Co., Ltd. Solid composition with improved solubility and absorbability
AU3461697A (en) * 1996-07-19 1998-02-10 Takeda Chemical Industries Ltd. Heterocyclic compounds, their production and use

Also Published As

Publication number Publication date
CN1487936A (zh) 2004-04-07
WO2002048142A1 (en) 2002-06-20
CA2431322A1 (en) 2002-06-20
NO20032614L (no) 2003-08-05
PL362172A1 (en) 2004-10-18
EP1350793A1 (en) 2003-10-08
HUP0400683A2 (hu) 2004-06-28
US20040053972A1 (en) 2004-03-18
AU2002221115A1 (en) 2002-06-24
KR20040025881A (ko) 2004-03-26

Similar Documents

Publication Publication Date Title
DK1524266T3 (da) Farmaceutisk sammensætning
NO20015175L (no) Farmasöytisk sammensetning
FI991485L (fi) Uusi farmaseuttinen koostumus
NO20025450L (no) Ny farmasöytisk sammensetning
DE60140246D1 (de) Wärmende Zusammensetzung
ATE490327T1 (de) Impfstoffzusammensetzung
DK1204410T3 (da) Farmaceutisk doseringsform med flere komponenter
NO20024175D0 (no) Azetidinderivater, deres fremstilling og farmasöytiske forbindelser inneholdende de samme
PL367180A1 (pl) Trwała kompozycja farmaceutyczna
FI20011478A0 (fi) Farmaseuttinen koostumus
ATE295081T1 (de) Hilfsstoff-zusammensetzung
DE60118008D1 (de) Pharmazeutische zusammensetzungen mit amlodipinmaleat
EE05020B1 (et) Glburiidi ravimkoostis
NO20032614D0 (no) Farmasöytisk sammensetning med forbedret absorbabilitet
FI20022128A7 (fi) Farmaseuttinen koostumus
DE69943245D1 (de) Gaserzeugende zusammensetzung
DE60129238D1 (de) Pharmazeutische zusammensetzung
DE60217390D1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
PT1227817E (pt) Composicao farmaceutica aquosa contendo ciclesonida
FI4488U1 (fi) Farmaseuttinen koostumus
EE200100281A (et) Analgeetiline ravimkoostis
PT1317256E (pt) Composição farmacêutica com veículo modificado
DE60020682D1 (de) Resorcinenthaltende zusammensetzung
ID27329A (id) Komposisi penghambat
DE10291905D2 (de) Pharmazeutische Zusammensetzung

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application